Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Syndax Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SNDX
Nasdaq
8731
https://syndax.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Syndax Pharmaceuticals Inc
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
- Apr 10th, 2024 8:05 pm
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
- Apr 8th, 2024 11:00 am
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Apr 5th, 2024 8:05 pm
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
- Mar 28th, 2024 1:54 pm
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
- Mar 28th, 2024 11:00 am
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
- Mar 26th, 2024 8:05 pm
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
- Mar 18th, 2024 11:00 am
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
- Mar 13th, 2024 12:54 pm
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript
- Mar 3rd, 2024 1:29 pm
Q4 2023 Syndax Pharmaceuticals Inc Earnings Call
- Feb 28th, 2024 6:10 pm
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
- Feb 27th, 2024 9:05 pm
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
- Feb 26th, 2024 1:50 pm
Syndax Announces Participation at Two Upcoming Investor Conferences
- Feb 26th, 2024 12:00 pm
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
- Feb 20th, 2024 9:05 pm
Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2024 9:05 pm
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
- Jan 2nd, 2024 12:00 pm
With 85% ownership of the shares, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is heavily dominated by institutional owners
- Dec 23rd, 2023 12:34 pm
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
- Dec 19th, 2023 9:16 pm
12 Most Promising Cancer Stocks According to Analysts
- Dec 18th, 2023 7:58 pm
Syndax Announces Pricing of $200 Million Public Offering of Common Stock
- Dec 15th, 2023 4:07 am
Scroll